Sequence: RRRVVVVVV
| Experiment Id | EXP002576 |
|---|---|
| Paper | Anti-cancer effect of R3V6 peptide-mediated delivery of an anti-microRNA-21 antisense-oligodeoxynucl |
| Peptide | R3V6 |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | not reported as molarity; complex prepared by weight ratio |
| Rna Concentration | 40 µg antisense-ODN per intratumoral injection |
| Mixing Ratio | antisense-ODN:R3V6 weight ratio 1:30 |
| Formulation Format | noncovalent peptide micelle/antisense-ODN complex |
| Formulation Components | R3V6 amphiphilic peptide complexed with anti-miR-21 antisense-ODN |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo glioblastoma xenograft therapeutic delivery |
| Cell Lines Or Primary Cells | |
| Animal Model | C6 glioblastoma subcutaneous xenograft in male BALB/c nude mice |
| Administration Route | intratumoral injection every 7 days; three total injections |
| Output Type | in vivo miR-21 knockdown, PDCD4 induction, apoptosis, tumor growth inhibition |
| Output Value | anti-miR-21/R3V6 significantly reduced miR-21 levels, increased PDCD4 staining, induced tumor apoptosis, and suppressed tumor growth/tumor weight compared with controls |
| Output Units | |
| Output Notes | delivery_success_class = 1 because functional in vivo anti-miR-21 delivery was demonstrated by reduced tumor miR-21, downstream PDCD4 induction, apoptosis, and tumor growth suppression. Scr-antisense-ODN/R3V6 control did not show significant tumor inhibition. |
| Toxicity Notes | No significant body-weight differences among animal groups, suggesting no obvious systemic toxicity under intratumoral dosing. |
| Curation Notes |